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THE NEED TO REEXAMINE GINA: A CALL FOR A 
BUSINESS NECESSITY EXCEPTION TO THE 
GENETIC INFORMATION NONDISCRIMINATION 
ACT 
Alyson Horn* 
INTRODUCTION 
With the passage of the Genetic Information Nondiscrimination Act 
(GINA or the Act) in 2008, it became a violation of federal law for 
employers to discriminate against employees or job applicants based on their 
genetic information.1  The Act prohibits employers from using genetic 
information in employment decisions and places restrictions on employers 
requesting or requiring genetic information as a condition of employment.  
Similar to the way in which the Americans with Disabilities Act (ADA) 
prevents employers from discriminating against employees on the basis of 
disabilities,2 GINA seeks to offer protection to individuals who may suffer 
discrimination on the basis of a genetic predisposition for a particular 
disease or condition.  While it offers a limited number of exceptions, GINA 
does not offer a business necessity exception as found under the ADA.3 
This Note argues that GINA is too limited and that there are certain 
workplace situations that necessitate a business necessity exception, or, 
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 1. Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. § 2000ff-1 
(2008). 
 2. Americans with Disabilities Act of 1990, 42 U.S.C. §§ 12101-12103, 12111-
12117 (2006). 
 3. Under the ADA, a business necessity exception allows employers to use 
qualification standards or other selection or screening criteria that exclude, or tend to 
exclude, an individual or a class of individuals with a disability because of their disability 
when the standards or criteria relate to an essential function of the job and a reasonable 
accommodation is not possible.  29 C.F.R. § 1630.10 (2011).  The concept of business 
necessity is explained in greater detail in section II.A. of this Note. 
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alternatively, an exception for when there is a direct threat to health and 
safety.  There is a particular need for such an exception in non-traditional 
work environments such as those faced by employees of the State 
Department, Peace Corps, and civilians in the Department of Defense 
(DOD).  While soldiers who are deployed to zones where malaria is 
prevalent (such as Afghanistan) are subject to glucose-6-phosphate 
dehydrogenase (G6PD) testing, the passage of GINA could now prevent 
similar testing of civilian Federal employees.4  A G6PD deficiency can 
produce a hematologic disorder, specifically hemolytic anemia, which can 
be seriously aggravated by primaquine, a medication routinely given to those 
who are in areas prone to malaria infections.5  If employees of the Foreign 
Service, Agency for International Development (USAID), and Peace Corps 
(who may be sent to many malaria-ridden regions of the world) cannot 
lawfully be tested for a G6PD deficiency, their health may be put at serious 
risk. 
Though decisions about military deployments for uniformed personnel 
can be informed by the results of this testing, civilian employees could 
potentially be prevented from obtaining the benefit from such preventive 
measures due to the restrictions imposed by GINA.6  The potential for 
serious medical complications for a G6PD-deficient employee given 
primaquine is a perfect example of a situation in which there is a clear 
benefit to amending GINA.  This Note advocates for the inclusion of a 
business necessity exception to the Act, proposing that the potential life-
saving consequences far outweigh the privacy and discrimination concerns 
that were the driving forces behind the Act. 
Section I of this Note begins with a discussion of the recent advances 
made in the world of genetics and the corresponding rise in the fear of 
potential discrimination based on a person’s genetic predisposition for a 
disease or condition.  Section II provides an overview of the legal options 
	  
 4. Clinton K. Murray, et al., Prevalence of Glucose-6-Phosphate Dehydrogenase 
Deficiency in U.S. Army Personnel, 171 MIL. MED. 905, 905 (2006). 
 5. Ernst Beutler, Glucose-6-Phosphate Dehydrogenase Deficiency: A Historical 
Perspective, 111 BLOOD J. 16, 16-17 (Jan. 2008), available at http://bloodjournal. 
hematologylibrary.org/content/111/1/16.full.pdf. 
 6. Compare Susannah Baruch & Kathy Hudson, Civilian and Military Genetics: 
Nondiscrimination Policy in a Post-GINA World, 83 AM. J. HUM. GENETICS 435, 437 
(2008) (stating that GINA does not apply to members of the United States Military, to 
veterans obtaining healthcare through the Department of Veterans Affairs, or to the 
Indian Health Service); see also the Act’s definition of “employee,” 42 U.S.C. 
2000ff(2)(A) (2008) (referring to the definition provided in 42 U.S.C. 2000e(f), which 
states that an employee “means an individual employed by an employer” and “include[s] 
employees subject to the civil service laws of a State government, governmental agency 
or political subdivision”). 
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considered to be potential shields against genetic discrimination, including 
the ADA, judicial interpretations, and Executive Order 13145.  A description 
of the major elements of GINA is then provided in Section III of this Note, 
including a brief discussion of the Act’s legislative intent.  Section IV delves 
more deeply into the why a business necessity exception is necessary, and 
begins with a brief medical overview of G6PD deficiency.  While no cases 
have gone to litigation on this matter, this Section also offers a case study of 
genetic discrimination in an employment claim made by a Peace Corps 
applicant who was denied placement in a malarial zone due to his G6PD 
deficiency.  Finally, turning to the potential negative consequences that may 
arise out of the disparate treatment of uniformed versus civilian employees 
with regards to G6PD testing, the facts are combined to make a case for a 
business necessity exception to GINA in order to ensure the safety of 
employees in the workplace. 
I. ADVANCES IN GENETIC KNOWLEDGE AND THE RESULTING FEAR OF 
DISCRIMINATION 
It is now widely known and accepted that the functioning of most living 
organisms is determined by the chemical compound Deoxyribonucleic acid 
(DNA).7  However, more than half a century ago scientists knew very little 
about the connection between genetics and disease.8  Giant leaps in scientific 
discovery took place between 1953, when James Watson and Francis Crick 
first described the double helix structure of DNA9 and 1990, when the 
National Institutes of Health and the Department of Energy collaborated 
with international partners on what is known as the Human Genome 
Project.10  The ambitious goal of this Project was to sequence the 3 billion 
base letters found in the complete set of DNA in the human body called the 
human genome.11  Finished in 2003, the ultimate aim of the study was to 
serve as a resource for a wide range of biomedical research, including the 
	  
 7. A Brief Guide to Genomics: DNA, Genes and Genomes, NAT’L HUM. GENOME 
RES. INST., NAT’L INSTS. HEALTH (last updated Apr. 14, 2014), 
http://www.genome.gov/18016863 (explaining that every DNA strand is comprised of 
four chemical units, called nucleotide bases, which comprise the genetic “alphabet.” The 
bases are “adenine (A), thymine (T), guanine (G), and cytosine (C)”).  
 8. NAT’L INSTS. HEALTH, HUMAN GENOME PROJECT FACT SHEET 1 (last updated 
Oct. 2010), http://report.nih.gov/NIHfactsheets/Pdfs/HumanGenomeProject(NHGRI).pdf. 
 9. Id. 
 10. Id. 
 11. Id.  The fact sheet compares the possession of a complete sequence of the human 
genome to having all required pages to a manual needed to make the human body.  It is 
the interpretation of this newly discovered content of these pages that is identified as the 
next challenge.  Id. 
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genetic variants that increase chances for the development of specific types 
of diseases, how the genome works and the genetic basis for health and 
disease.12  Due to the work of the Human Genome Project, researchers have 
discovered more than 1,800 disease genes and now have the ability to find a 
gene suspected of causing an inherited disease in a matter of days, rather 
than the years it took previously.13  At present, less than ten years after the 
Project’s completion, the process of genetic sequencing is much faster and a 
great deal less costly, and some predict we are not too far off from the 
$1,000 genome.14 
A. The Current State of Genetic Testing 
More than 2,000 tests have been developed to detect a large number of 
genetic conditions, enabling patients to learn their risks for diseases and 
assisting doctors with a more accurate diagnosis.15  The process of genetic 
testing gathers cells from an individual through various means including 
from samples of blood, “saliva, the inside of the cheek, or any other 
tissue.”16  While a positive test result for certain genetic mutations is nearly 
determinative of the possibility of manifesting that disorder, like the test for 
Huntington’s Disease, genetic tests for other conditions like breast cancer, 
cystic fibrosis and Alzheimer’s Disease are less than certain.17  However, the 
	  
 12. A Brief Guide to Genomics: DNA, Genes and Genomes, supra, note 7. 
 13. HUMAN GENOME PROJECT FACT SHEET, supra note 8, at 1. 
 14. As Genetic Sequencing Spreads, Excitement, Worries Grow, NAT’L PUB. RADIO 
(Sept. 18, 2012, 3:34 AM), http://www.npr.org/templates/transcript/transcript 
.php?storyId=160958948 (statement by NPR’s Rob Stein, stating that the current cost per 
individual gene sequencing is approximately $4,000); see also Eryn Brown, What a 
$1,000 Genome Could Mean for Medicine, L.A. TIMES  (Jan. 10, 2012), 
http://articles.latimes.com/2012/jan/10/news/la-heb-1000-dollar-genome-20120110 
(explaining that biotechnology firms have been on the quest to offer machines capable of 
sequencing a human genome in about one day at a cost of approximately $1,000, with the 
idea that the price drop will enable doctor’s to provide a more “personalized medicine” 
for more accurate patient diagnosis and care). 
 15. HUMAN GENOME PROJECT FACT SHEET, supra note 8; see also A Brief Guide to 
Genomics: DNA, Genes and Genomes, supra note 7 (noting that genome-based research 
is enabling medical researchers “to develop more effective diagnostic tools, to better 
understand the health needs of people based on their individual genetic make-ups, and to 
design new treatments for disease”). 
 16. Paul Steven Miller, Is there a Pink Slip in My Genes?  Genetic Discrimination in 
the Workplace, 3 J. HEALTH CARE L. & POL’Y 225, 229-30 (2000). 
 17. Id. at 230-31 (stating that while a person who tests positive for the Huntington’s 
Disease gene will develop the disease by middle age with a “chilling certainty,” a woman 
who tests positive for a type of gene mutation known as the BRCA 1 mutation will have 
an eighty percent chance of developing breast cancer if there is a clear history of breast 
cancer in her family). Tests can additionally be used to identify carriers of certain types 
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common misperception is that genetic testing offers a completely accurate 
prediction as to whether an individual will manifest a genetic disease or 
condition that could lead to discrimination.18 
B. Fear Engendered by Newly Available Genetic Information 
Unfortunately, history has proven that the specter of genetic 
discrimination is a real concern.19  For example, out of the mistaken belief 
that heredity was the cause of criminality, mental conditions and pauperism, 
Indiana passed the first state eugenic law in 1907, mandating forced 
sterilizations.20  The U.S. Supreme Court soon after sanctioned this type of 
practice in its 1927 decision, Buck v. Bell, holding that states could 
involuntarily sterilize individuals based on their so-called flawed genetics.21  
In discussing Carrie Buck, who like her mother, was committed to the 
Virginia State Colony for Epileptics and Feeble Minded, Justice Holmes 
rationalized the holding by stating that, “[t]hree generations of imbeciles are 
enough.”22  Even as recently as the 1970s, state legislatures enacted 
mandatory screening laws with the goal of identifying those with sickle cell 
anemia with the hope of reducing the incidence of the disease.23  The fact 
	  
of disease or conditions.  Carriers may never actually develop the disease, but may still 
possess the recessive genes and pass them onto their children who may go on to develop 
the condition.  Id. at 229. 
 18. Id. at 232 (explaining that there are a variety of factors at play beyond a genetic 
disposition for the disease, that influence its severity, the timing of its onset, and 
ultimately, whether the disease will ever actually manifest itself at all). 
 19. Statement on Genetic Discrimination in Health Insurance, AM. ASS’N FOR THE 
ADVANCEMENT OF SCI., http://www.aaas.org/page/statement-genetic-discrimination-
health-insurance (last visited Mar. 26, 2014). 
 20. Lutz Kaelber, Eugenics/Eugenic Sterilization in Indiana, U. VT., 
http://www.uvm.edu/~lkaelber/eugenics/IN/IN.html (last visited Mar. 26, 2014). 
 21. Jessica L. Roberts, The Genetic Information Nondiscrimination Act as an 
Antidiscrimination Law, 86 NOTRE DAME L. R. 597, 608 (2011). 
 22. Buck v. Bell, 274 U.S. 200, 207 (1927) (justifying decision by stating that forced 
sterilization is a better societal solution than the alternative which would involve “waiting 
to execute degenerate offspring for crime [or letting] them starve for their imbecility”). 
 23. Genetic Screening and Discrimination: Relevance of Historical Experience, 
NAT’L HUM. GENOME RES. INST., NAT’L INSTS. HEALTH, http://www.genome.gov/ 
25019904 (last updated Apr. 2, 2012) (explaining that an inadequate level of education 
and counseling led to confusion about the sickle cell trait and actual sickle cell disease).  
Sickle cell anemia is the most common form of sickle cell disease and the disorder causes 
the normally doughnut-shaped red blood cells to resemble a crescent, or “sickle.” The 
abnormally shaped cells die at a much faster rate than they can be replaced, and those 
suffering from the condition can experience chronic pain and/or fatigue. What is Sickle 
Cell Anemia, NAT’L HEART, LUNG, & BLOOD INST., NAT’L INSTS. HEALTH, 
http://www.nhlbi.nih.gov/health/health-topics/topics/sca/ (last visited Nov. 14, 2012). 
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that African Americans were disproportionately affected, along with the 
inadequate privacy measures with regards to the results of these tests, gave 
rise to a legitimate fear in lawmakers that there was a real possibility this 
would lead to discrimination in employment.24  Ultimately, Congress passed 
the National Sickle Cell Anemia Control Act in 1972, which withheld 
federal funding from those states that utilized mandatory testing.25 
While the past few decades have been an extremely exciting time in 
scientific discovery, it is nonetheless unsurprising that many individuals 
have grown concerned about the possibility of genetic discrimination.26  For 
example, from 2001-2003, over 86,000 adults were surveyed about their 
willingness to undergo genetic testing, and forty percent of the participants 
revealed they did not believe such testing was a good idea, mostly due to 
fear of losing insurance coverage.27  Similarly, results in several studies 
conducted by the Genetics and Public Policy Center at Johns Hopkins 
University showed an increasingly high level of public concern about an 
employer having access to genetic information, rising from eighty-six 
percent in 2002 to ninety-two percent in 2004.28  These concerns extend to 
health care professionals as well, with one study showing that 108 of 159 of 
genetic counselors29 would not submit charges for genetic tests to insurance 
companies out of fear of possible discrimination.30  Even more worrisome 
were those studies showing that individuals were deciding to forgo genetic 
	  
 24. Baruch & Hudson, supra note 6, at 436; Melinda B. Kaufmann, Genetic 
Discrimination in the Workplace: An Overview of Existing Protections, 30 LOY. U. CHI. 
L.J. 393, 402-03. 
 25. Ingrid Lobo, Genetic Testing, SCITABLE BY NATURE EDUC., NATURE, 
http://www.nature.com/scitable/spotlight/genetic-testing-13782065 (last visited Apr. 14, 
2014); National Sickle Cell Control Act of 1972, Pub. L. No. 92-294, 86 Stat. 136. 
 26. Louise McIntosh Slaughter, Genetic Testing and Discrimination: How Private Is 
Your Information? 17 STAN. L. & POL’Y REV. 67, 70-71 (2006). 
 27. Id. at 71 (explaining that this type of reluctance is detrimental to America’s 
public health and the potential future benefits of scientific research). 
 28. Id. 
 29. Genetic counseling is described as: 
[T]he professional interaction between a healthcare provider with specialized 
knowledge of genetics and an individual or family.  The genetic counselor 
determines whether a condition in the family may be genetic . . . [whether] 
another relative may be affected . . . and offer[s] and interpret[s] genetic tests 
that may help eliminate risk of disease. 
Genetic Counseling, Talking Glossary of Genetic Terms, NAT’L HUMAN GENOME RES. 
INST., NAT’L INSTS. HEALTH, http://www.genome.gov/Glossary/index.cfm?id=79 (last 
visited Nov.12, 2012). 
 30. Slaughter, supra note 26, at 71. 
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testing altogether due to the potential for discrimination, even if the early 
detection of a genetic mutation could help in preventing an early death.31	  
II. LEGAL OPTIONS PRIOR TO GINA 
A. The Americans with Disabilities Act (1990) 
Out of this concern for possible discriminatory use of genetic information 
arose a search for legislative guidance on the issue.  In offering protection 
against discrimination based on disabilities, the ADA was viewed as a 
possible shield against genetic discrimination.32  Enacted in 1990, the ADA 
was the Congressional response to the growing concern that people with 
disabilities were facing discrimination and a lack of employment 
opportunities.33  After its passage, an employer was no longer able to make a 
request for medical information prior to extending an offer of employment.34  
After an offer of employment has been made, however, an employer may 
conduct or request a medical examination to determine whether the 
employee may perform the essential functions of the job.35  If required, the 
exam must be given to all entering employees and the employer must 
demonstrate that the reason for the exam is both job-related and consistent 
with business necessity.36  Based on the results of these pre-employment 
exams, the employer is permitted to screen out those with disabilities who 
cannot meet qualification standards or who cannot perform the essential 
functions of the job even with reasonable accommodation.37  Furthermore, 
the employer is permitted to screen out those who would pose a “direct 
threat to the health or safety of other individuals in the workplace.”38  The 
ADA defines “direct threat” in the statute as “a significant risk to the health 
	  
 31. Slaughter, supra note 26, at 71 (outlining further that twenty-five percent of 
respondents said they would use an alias to obtain a genetic test while sixty percent 
indicated they would not share the information with a colleague out of privacy concerns 
and fear of discrimination). 
 32. U.S. EEOC, Notice No. 915.002, Policy Guidance on Executive Order 13,145: 
To Prohibit Discrimination in Federal Employment Based on Genetic Information (July 
26, 2000), available at 2000 WL 33407180. 
 33. Americans with Disabilities Act of 1990, 42 U.S.C. §§ 12101-12113 (2000); see 
also Nicole Silvestri, Echazabal and the Threat to Self-Defense: The Most Recent Call 
for a Consistent, Interstate Genetic Non-Discrimination Policy, 7 U. PA. J. LAB. & EMP. 
L. 409, 413 (2005) (describing the ADA as one of the first “empowering pieces of 
disability legislation”). 
 34. 42 U.S.C. § 12112(d)(2)(A) (2000). 
 35. Id. at § 12112(d)(4)(A). 
 36. Id. at § 12112(d)(3)-(4)(A). 
 37. Id. at § 12112(b)(5)(A). 
 38. 42 U.S.C. § 12113(b). 
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or safety of others that cannot be eliminated by reasonable 
accommodation.”39  The Equal Employment Opportunity Commission 
(EEOC) regulations expanded the statutory definition to include a threat-to-
self situation,40 an expansion upheld by the Supreme Court in Chevron USA 
Inc. v. Echazabal.41  In this case, Echazabal, a long-time oil refinery worker, 
brought suit when his offer of employment from Chevron was revoked after 
he failed a required medical exam showing that he had asymptomatic, 
chronic active hepatitis C.42  The Court clarified that a direct threat is one 
that is “made on the basis of individualized risk assessments,” and upheld 
Chevron’s decision to withdraw the offer on the basis that exposure to 
solvents and chemical in the oil refinery process could worsen his condition, 
or in other words, that it would be a threat to the employee himself.43 
In Bragdon v. Abbot, the Supreme Court addressed the idea that the ADA 
also covers discrimination for a condition that has not yet manifested itself 
by demonstrating actual physical symptoms.44  In this case, the plaintiff 
brought suit against her dentist for his refusal to fill a cavity due to her HIV 
positive status.45  Though her condition had not manifested itself as full-
blown AIDS, the Court found that someone infected with HIV qualified as 
“disabled” under the ADA since it “substantially limits” life activities.46  
Justice Rehnquist urged caution in his partial dissent, however, arguing that 
if “taken to its logical extreme [the majority opinion] would render every 
	  
 39. Id. 
 40. 29 C.F.R. § 1630.2. 
 41. Silvestri, supra note 33, at 422 (explaining that this more expansive definition 
was first put forward by the EEOC in its interpretation of the statutory language of the 
ADA); see also Chevron USA Inc. v. Echazabal, 536 U.S. 73, 81-82 (2002) (concluding 
that the Congressional omission of the threat-to-self-language does not preclude it from 
being included in a more expansive understanding of legislative intent). 
 42. Silvestri, supra note 33, at 422-23.  Echazabal was tested each of the two times 
he applied for a position with the company and the exams showed liver abnormality 
and/or function.  The cause was later determined to be from Hepatitis C.  Chevron, 536 
U.S. at 76. 
 43. Chevron, 536 U.S. at 86 (clarifying that the defense must be “based on a 
reasonable medical judgment that relies on the most current medical knowledge and/or 
the best available objective evidence”). 
 44. Ashley M. Ellis, Genetic Justice: Discrimination by Employers and Insurance 
Companies Based on Predictive Genetic Information, 34 TEX. TECH L. REV. 1071, 1086 
(2003). 
 45. Bragdon v. Abbot, 524 U.S. 624, 628-29 (1998).  The dentist stated that he was 
willing to fill the cavity at the local hospital with no extra charge, however, the plaintiff 
would be responsible for covering the cost of using the hospital facilities. Id. at 628. 
 46. Id. at 630 (clarifying that due to the immediacy of the damage to an affected 
individual’s white blood cells, HIV is to be determined as “an impairment from the 
moment of infection”). 
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individual with a genetic marker for some debilitating disease ‘disabled’ 
here and now because of some future effects.”47  This dissenting argument 
engendered a level of concern, for some, as to whether the ADA would, in 
fact, be a meaningful tool in combating genetic discrimination.48	  
B. Executive Order 13,145 
Recognizing the lack of a comprehensive federal legislative response to 
genetic discrimination, on February 8, 2000, President Clinton signed 
Executive Order 13,145 to address the issue in the federal workforce.49  The 
Order prohibits federal employers from using “protected genetic 
information” along with information from genetic testing, including genetic 
testing of family members, in employment decisions.50  This prohibition 
includes using genetic information as a basis for a refusal to hire or a 
decision to fire, as well as its use in depriving an employee of workplace 
opportunities.51  In its limited application to those employees who work for 
federal agencies, however, the Order fell short of offering a more 
widespread protection against genetic discrimination.52 
III. THE GENETIC INFORMATION NONDISCRIMINATION ACT (2008) 
A. Legislative Intent 
The “patchwork of laws and interpretations”53 on the issue of genetic 
discrimination finally received a comprehensive federal legislative response 
	  
 47. Id. at 661 (Rehnquist, J., concurring in part and dissenting in part) (contending 
that the plaintiff was unable to demonstrate how she was “utterly unable” to engage in 
those activities identified by the majority). 
 48. Baruch & Hudson, supra note 6, at 437. 
 49. Exec. Order No. 13,145, 65 Fed. Reg. 6877 (Feb. 8, 2000), reprinted as amended 
in 42 U.S.C. § 2000e-16 (2003).  The Executive Order states, in relevant part: 
It is the policy of the Government of the United States to provide equal 
employment opportunity in Federal employment for all qualified persons and 
to prohibit discrimination against employees based on protected genetic 
information, or information about a request for or the receipt of genetic 
services. This policy of equal opportunity applies to every aspect of Federal 
employment. 
Id. 
 50. Id. 
 51. Id. 
 52. Silvestri, supra note 33, at 418. 
 53. Slaughter, supra note 26, at 72.  Rep. Slaughter was a sponsor of GINA, first 
proposing the bill in 1995. Phillip K. Vacchio & Joshua L. Wolinsky, Genetic 
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with the passage of GINA in 2008.54  Hailed by former Senator Edward 
Kennedy of Massachusetts as “the first major new civil rights bill of the new 
century,”55 GINA offers protection from genetic discrimination by both 
insurers and employers.56  It was a hard-fought, multi-year battle, with 
opponents from the insurance industry and employers arguing that existing 
legislation rendered the Act’s passage unnecessary and that to do so “would 
only create confusion and unnecessary costs.”57  Furthermore, employers 
argued that the limited number of cases brought on the subject demonstrated 
that genetic discrimination was not common enough in the workplace to 
warrant its own legislation.58 
The situation facing Phil Hardt, a man who tested positive for the 
Huntington’s Disease genetic mutation, paints the story another way.59  
Confronted not just with the reality of his personal health discovery, Mr. 
Hardt also had contend with the fact that his daughter was denied health 
insurance due to her genetic predisposition for the disease that was 
discovered as a direct result of his diagnosis.60  Congress recognized the 
importance of offering comprehensive protection against genetic 
discrimination for just this sort of situation, and wanted to provide a way for 
the public to take advantage of the benefits of genetic testing without fear of 
reprisal by insurance companies or in the workplace.61  Due to the limited 
documentation of genetic discrimination occurring in the workplace, the Act 
was seen as being a preemptive measure intended to circumvent a type of 
discrimination that may take place in the future, not one that has existed in 
recent history.62  Senator Kennedy explained that with the passage of GINA, 
	  
Information Nondiscrimination Act of 2008: It’s in Title VII’s Genes, 29 HOFSTRA LAB. & 
EMP. L.J. 229, 231 (2011). 
 54. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, §2(5), 
122 Stat. 881, 882-83. 
 55. Joanne Barken, Judging GINA: Does the Genetic Information Nondiscrimination 
Act of 2008 Offer Adequate Protection?, 75 BROOKLYN L. REV. 545, 550 (2009). 
 56. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, §2(5), 
122 Stat. 881, 882-83. 
 57. Barken, supra note 55, at 550. Passage of the bill required thirteen years of 
Congressional debate as to whether there was an actual need for federal legislative 
protection against genetic discrimination.  It was further argued that the bill was overly 
broad and would require employers to cover too wide a range of genetic disorder.  Id. 
 58. Id. (explaining the employers also maintained that access to genetic information 
in certain employment decisions was crucial, allowing them to both lower the potential 
costs of future healthcare needs and to prevent paying out for excessive sick leave). 
 59. Vacchio & Wolinsky, supra note 53, at 232. 
 60. Id. 
 61. Id. (explaining that one of the major goals of the legislation was to provide a 
standard that was both national and uniform). 
 62. Id. 
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the door has been “open[ed] to modern medical progress for millions and 
millions of Americans.”63  Indeed, the greater the number of individuals who 
take advantage of genetic testing, the greater the pool of information for 
researchers to use in order to perfect and refine a diagnosis based on 
genetics.64	  
B.  Summary of the Law 
GINA is divided into two sections and Title I focuses on health insurance, 
prohibiting group health plans and health insurance providers offering group 
coverage from establishing rules of eligibility or altering premium amounts 
for an individual on the basis of genetic information.65  Title II focuses on 
the workplace, prohibiting employers from using genetic information in 
employment-related decisions, including as a justification for not hiring an 
individual, a reason to discharge an employee, or with respect to 
compensation or the terms and conditions of employment.66  Further, this 
prohibition extends to any employer requesting that an individual undergo a 
genetic test or actively seeking and purchasing genetic information about its 
employees.67 
GINA defines “genetic information” as information on the genetic tests of 
an individual or of an individual’s family members, including information 
on those family members who have already manifested a disease or 
condition.68  This encompasses the request or receipt of the genetic 
information of an individual, or of an individual’s family member’s genetic 
information, including testing, counseling, education, and participation in 
clinical research that involves genetic services.69  In practice, this definition 
	  
 63. Id. 
 64. Id. at 233. 
 65. 42 U.S.C. § 300gg-53(a)-(b) (2012). 
 66. 42 U.S.C. § 2000ff-1(a) (2012).  The statute outlines that it is unlawful for 
employers: 
(1) [T]o fail or refuse to hire, or to discharge, any employee, or otherwise to 
discriminate against any employee with respect to the compensation, terms, 
conditions, or privileges of employment of the employee, because of genetic 
information with respect to the employee; or (2) to limit, segregate, or classify 
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deprive any employee of employment opportunities or otherwise adversely 
affect the status of the employee as an employee, because of genetic 
information with respect to the employee. 
Id. at §§ 2000ff-1(a)(1)-(2). 
 67. 42 U.S.C. § 2000ff-1(b) (2012). 
 68. Id. at § 2000ff (4)(A) (2012). 
 69. Id. at § 2000ff (4)(B) (2012).  “Such term includes, with respect to any 
individual, any request for, or receipt of, genetic services, or participation in clinical 
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would even include a company doctor from taking an employee’s family 
medical history as part of a routine examination.70  While also including 
genetic information about a fetus that is carried by a covered individual,71 
the Act specifically excludes information pertaining to both sex and age.72  
Furthermore, GINA does not offer coverage for individuals who have 
manifested physical symptoms of a disease, even if it is genetically linked, 
as such an instance would be covered under the protections of the ADA.73	  
GINA does, however, provide for six very limited exceptions to this 
rule.74  First, an employer is exempt from the rule’s requirements when it 
inadvertently requests family medical information.75  Nor is it a violation to 
receive aggregate information about employees under the following 
conditions: 1) When an employer provides or sponsors a health or genetic 
service or program; 2) the employee provides voluntary, written 
authorization for employers to obtain family genetic information obtained 
through that service; 3) only the employee and health care professional 
receive individually identifiable information on those services rendered; and 
4) the employer only receives information that pertains to those services that 
is in the aggregate form, and does not disclose the identities of individual 
participants in the employer-provided health service.76  Furthermore, 
employers are authorized to request family medical information in order to 
comply with the Family and Medical Leave Act of 1993.77  Employers are 
	  
research which includes genetic services, by such individual or any family member of 
such individual.” Id. 
 70. Id. at §2000ff-1(b). 
 71. Id. at § 2000ff-8(b)(1) (2012). 
Any reference in this chapter to genetic information concerning an individual 
or family member of an individual shall—(1) with respect to such an 
individual or family member of an individual who is a pregnant woman, 
include genetic information of any fetus carried by such pregnant woman; and 
(2) with respect to an individual or family member utilizing an assisted 
reproductive technology, include genetic information of any embryo legally 
held by the individual or family member. 
Id. 
 72. Id. at § 2000ff(4)(C) (20012). 
 73. Abigail Lauren Perdue, Justifying GINA, 78 TENN, L. REV. 1051, 1065 (2011); 
see also Jessica L. Roberts, The Genetic Information Nondiscrimination Act as an 
Antidiscrimination Law, 86 NOTRE DAME L. REV. 597, 625 (2011) (explaining that the 
ADA can be understood as retrospective in application, looking to existing discrimination 
to justify protecting against future harm, while GINA is more forward looking in its 
attempt to preempt discrimination before it becomes entrenched). 
 74. 42 U.S.C. §§ 2000ff-1(b)(1)-(6). 
 75. Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. § 2000ff-1(b)(1). 
 76. Id. at § 2000ff-1(b)(2). 
 77. Id. at § 2000ff-1(b)(3). 
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not prohibited from purchasing commercially and publicly available 
documents that contain family medical information of an employee.78  An 
employer may also require genetic information from an employee if it is 
used to genetically monitor the biological effects of toxic substances in the 
workplace, provided the employer gives written notice and obtains a 
voluntary and written authorization from the employee.79  Finally, employers 
may conduct DNA analysis for law enforcement purposes or when necessary 
to identify human remains.80	  
IV. THE CASE FOR A BUSINESS NECESSITY EXCEPTION TO GINA 
In response to the fearful environment created by the potential for genetic 
discrimination and the possibility of stifling unprecedented scientific 
discovery, Congress omitted a business necessity exception to GINA.81  In 
fact, in a 2009 EEOC hearing on the proposed rule to implement the Act, 
Jeremy Gruber of the National Council for Responsible Genetics echoed this 
sentiment that informed the legislation, stating that, “over the course of 
many years it was very difficult for even the best minds to come up with 
ways or examples” where a job-related, business necessity exception would 
be necessary.82  Congress, however, was too limited with its exceptions to 
GINA and, like with the ADA,83 GINA would benefit from the addition of a 
business necessity exception.84  In lieu of a general business necessity 
exception, Congress should, at a minimum, adopt the ADA’s direct threat to 
the health and safety of self or others standard.   
	  
 78. Id. at § 2000ff-1(b)(4); see generally Family and Medical Leave Act of 1993, 
Pub. L. No. 111-84, 123 Stat. 124.  
 79. 42 U.S.C. § 2000ff-1(b)(5). 
 80. Id. at § 2000ff-1(b)(6). 
 81. Notice of Proposed Rulemaking Implementation of Title II of the Genetic 
Information Non-Discrimination Act of 2008 (Commission Meeting of February 25, 
2009), transcript available at: http://www1.eeoc.gov//eeoc/meetings/2-25-
09/transcript.cfm?renderforprint=1 [hereinafter Notice of Proposed Rulemaking].  Jeremy 
Gruber is President and Executive Director of the Council for Responsible Genetics.  He 
has worked extensively on the issue of genetic discrimination, including working closely 
with members of Congress and their staff on the language of GINA as well as on strategy 
and support.  Further, he is a founding member of the Coalition for Genetic Fairness, a 
group of 500 organizations that advocated on Capitol Hill for the passage of GINA.  
Board of Directors and Emeriti, COUNCIL FOR RESPONSIBLE GENETICS, http://www. 
councilforresponsiblegenetics.org/Help/Directors.aspx (last visited Dec.17, 2012). 
 82. Notice of Proposed Rulemaking, supra note 81. 
 83. Title VII of the Civil Rights Act of 1964 also has a business necessity exception, 
applicable to disparate impact.  42 U.S.C. § 2000e-2(k). 
 84. See generally 42 U.S.C. § 12112(d)(4)(A) (2000). 
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Situations do in fact exist where genetic testing by an employer could 
prevent a threat to the health of an employee.85  Multiple situations arise 
where a business necessity defense could be justified on this grounds.86  One 
of the most dramatic situations implicated by the absence of a business 
necessity/direct threat exception is where an employee’s health is 
endangered by the inability to receive a genetic test (or by the fear of 
offering a test that could be deemed a genetic test).  As referenced 
previously, this is a situation faced by employees of the State Department, 
Peace Corp, USAID, and civilians in the DOD operating in malaria-infested 
parts of the world.  However, individuals such as these could avoid an 
adverse reaction to a common anti-malaria medication if limited genetic 
testing were permitted as part of a business necessity exception to GINA.87 
A. G6PD Deficiency 
G6PD deficiency is the most common enzyme deficiency in the world, 
and “[a]pproximately 400 million people are affected worldwide.”88  This 
deficiency occurs with more frequency throughout Asia, Africa, the 
Mediterranean, and the Middle East.89  In the United States it is estimated 
that ten percent of African American males are affected.90  The condition 
primarily affects red blood cells, which are responsible for carrying oxygen 
from the lungs to the rest of the body.91  A defect in the G6PD results in a 
premature breakdown of these cells at a much faster rate than the body is 
capable of replacing them.92 
Though the carriers of this deficiency are often asymptomatic, in certain 
instances acute hemolysis can occur.93  Hemolysis (or hemolytic anemia) is 
characterized by the breakdown of the red blood cells94 and can cause 
“paleness, yellowing of the skin and whites of the eyes (jaundice), dark 
	  
 85. See generally Chevron USA Inc. v. Echazabal, 536 U.S. 73 (2002). 
 86. For example, there could be instances where taking a family medical history 
could be important to evaluating an individual’s ability to safely perform a job. 
 87. Baruch & Hudson, supra note 6, at 438. 
 88. Jennifer E. Frank, Diagnosis and Management of G6PD Deficiency, 72 AM. 
FAMILY PHYSICIAN 1277, 1277 (2005). 
 89. Id. 
 90. Id. 
 91. Glucose-6-phosphate Dehydrogenase Deficiency, GENETICS HOME REFERENCE, 
NAT’L INSTS. HEALTH (last updated Aug. 18, 2014), http://ghr.nlm.nih.gov/condition 
/glucose-6-phosphate-dehydrogenase-deficiency. 
 92. Id. 
 93. Frank, supra note 88, at 1277. 
 94. Hemolysis, MEDLINE PLUS, NAT’L INSTS. HEALTH, http://www.nlm.nih.gov/ 
medlineplus/ency/article/002372.htm (last updated Feb. 8, 2012). 
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urine, fatigue, shortness of breath and a rapid heart rate.”95  While rarely 
fatal, there are extreme cases where a severe reaction can necessitate a life-
saving blood transfusion.96  Differing types of gene mutations associated 
with this condition dictate the level of deficiency and the resulting severity 
of symptoms experienced by the individual.97  Adverse reactions within 
carriers of this condition are often the result of exposure to certain oxidative 
stressors, including infection, oxidative drugs, or fava beans.98  Generally, 
“treatment is geared towards avoidances of these and other stressors.”99  An 
example of an oxidative drug that may trigger a reaction in someone with 
this condition is the common anti-malaria drug, primaquine.100  This drug, in 
fact, has been identified by some sources as being the most common agent 
leading to hemolysis in G6PD-deficient persons.101 
B.  G6PD Testing as Potential Genetic Discrimination 
While no case has been litigated on the subject of whether G6PD testing is 
a form of genetic discrimination, early in 2012 a complaint was filed in the 
United States District Court for the Southern District of New York alleging 
that the United States Peace Corps violated GINA when it based an 
employment decision on the results of a G6PD test.102  The complainant, 
Imoite Ipaalinyang Omulepu, applied for a Peace Corps Response Kavango 
Basket Liaison position based in northern Namibia in March of 2011.103  
Omulepu was ultimately offered a position as a Peace Corps Response 
Volunteer (PCRV); however, his final acceptance was contingent upon 
successful completion of all legal and medical clearances.104  Pursuant to the 
provided instructions, the complainant completed the required medical 
	  
 95. Frank, supra note 88, at 1277. 
 96. Id. 
 97. Id. (explaining that individuals who are homozygous for the deficiency typically 
have more severe reactions that those who are heterozygous). 
 98. Id. 
 99. Id. 
 100. Murray, supra note 4.  Primaquine, the brand name for primaquine phosphate, is 
used with other medications to both prevent and treat malarial infections that are a result 
of mosquito bites.  Primaquine focuses on destroying the parasites that cause malaria.  
Primaquine, MEDLINE PLUS, NAT’L INSTS. HEALTH, http://www.nlm.nih.gov/medlineplus/ 
druginfo/meds/a607037.html (last visited Apr. 20, 2014). 
 101. Id.  G6PD deficiency was first discovered, in fact, out of an investigation of 
cases of hemolytic anemia occurring in some individuals being treated for malaria with 
the same class of drugs.  Beutler, supra note 5, at 16. 
 102. Complaint, Omulepu v. United States Peace Corps, No. 1:12-cv-00988 
(S.D.N.Y. Feb.7, 2012), ECF No. 2, available at 2012 WL 5215600. 
 103. Id. at 4. 
 104. Id. at 5. 
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examination and tests, which included a screening for G6PD deficiency.105  
Omulepu tested positive for the deficiency, both in the initial blood test and 
a subsequent re-testing, which was undertaken to rule out the possibility that 
the initial results indicated a false positive.106 
A nurse employed by the Peace Corps informed the complainant that the 
agency had implemented a new policy in 2008 that stated individuals who 
tested positive for the G6PD deficiency were ineligible to serve in malaria-
endemic countries.107  Based on the two sets of test results, the Peace Corps 
Pre-Service Review Board was unable to clear Omulepu for service in 
Namibia.108  The Board offered the complainant the opportunity for appeal, 
but despite a letter from a hematologist stating that Omulepu was not at 
significant risk for “significant primaquine induced hemolysis,” the Board 
denied his appeal.109  He was not, however, deemed ineligible to work for 
the Peace Corps and was informed he had the opportunity to serve as a 
PCRV in areas outside malaria zones.110  Omulepu claimed that the Peace 
Corps violated GINA, in part, by allowing its employment decision to be 
based on the results of a genetic test.111  He further claimed that as a result of 
this action, he suffered a lack of employment opportunities while his 
confidence in seeking a career path on the African continent was 
diminished.112 
In its response to the complainant’s filing, the Peace Corps asserted that 
its guideline for G6PD deficiency was informed by recommendations made 
by the Center for Disease Control and Prevention (CDC).113  It cited CDC 
literature indicating that primaquine is contraindicated in people with the 
deficiency, and accordingly, the Peace Corps will not place such people in a 
malarial area where primaquine is required due to the health concerns that 
may arise.114  In addition, the Peace Corps contended that it did not obtain 
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 106. Id. at 5-6. 
 107. Id. at 6. 
 108. Complaint at 6, Omulepu v. United States Peace Corps, No. 1:12-cv-00988 
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 113. Id. at 3. 
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any genetic information from Omulepu, but rather only required a blood test 
to determine whether there was a deficiency in the G6PD enzyme.115  The 
agency further denied use of the test as the basis of its employment decision, 
as Omulepu was offered the opportunity to pursue alternative PCV positions 
outside malarial zones.116  Finally, the Peace Corps maintained that, if GINA 
were to prohibit the use of such a blood test, the agency would be put in a 
position in which it may place PCVs in areas where there is an increased risk 
of serious health consequences.117  Accordingly, the Peace Corps asserted 
that placing volunteers in malaria-endemic countries without the G6PD 
testing would be acting both irresponsibly and medically unethically.118 
This case was never brought to trial; a Stipulation and Order of Settlement 
and Dismissal was filed on September 4, 2012.119  According to the terms of 
the settlement, the action was dismissed with prejudice against the Peace 
Corp “without costs or disbursements.”120  Furthermore, the terms mandated 
that as soon as practicable after the date of the Order, the Agency shall use 
its “best efforts” in order to place Omulepu in a PCV position.121  
Significantly, the settlement called for the Peace Corps to place the 
complainant in a malarial region, despite his G6PD deficiency.122  While 
settlement of the case prevented a ruling on whether the Peace Corps’ 
actions constituted genetic discrimination under GINA, the settlement may 
very well lead to more employers being forced to place employees in harm’s 
way, despite their reasoned assessment of the dangers of the situation. 
C.  G6PD Testing and the Military 
The lengthy amount of time that the United States has recently spent in 
both Iraq and Afghanistan, and the resulting strain on our military, has the 
	  
Peace Corps, Dr. Barry Simon asserted that it would be a violation of medical ethics to 
administer Primaquine to an individual such as the complainant.  
 115. Id. at 8.  This Note takes no position on the legal question of whether a G6PD 
test is a genetic test under GINA (on which there is no case law or other legal guidance). 
 116. Id. at 9. 
 117. Id. 
 118. Id. 
 119. Stipulation and Order of Dismissal, Omulepu v. United States Peace Corps, No. 
1:12-cv-00988 (S.D.N.Y. Sept. 14, 2012) (on file with author). 
 120. Id. 
 121. Id. 
 122. Id.  The order stipulates, however, that it does not constitute an admission of 
liability or fault of any party, nor does it constitute an admission of liability or fault on 
behalf of any of their departments, agencies, offices, agents, officials, or employees.  Id. 
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DOD looking to civilian employees to fill in the manpower gaps.123  
Currently, it is DOD policy to rely on a mix of “capable military members 
and DoD civilian employees to meet DOD global national security mission” 
needs.124  DOD identifies safeguarding the health of its deployed civilian 
employees as a matter of serious concern, and requires such employees to 
undergo an annual medical assessment to determine eligibility for worldwide 
deployment.125  While GINA’s restrictions do not apply to uniformed 
members of the military, its regulations still apply to DOD civilian 
employees.126 
As explained in a 2006 seminar focusing on genetics perspectives on 
policy, the members of the military are thought to require “special 
[consideration] because they face ‘unusual occupational health challenges,’” 
due to their assignment to a vast range of jobs in a vast range of 
environments.127  It is standard for the military to collect DNA samples for 
identification purposes should a service member die in battle.128  A positive 
result for a genetic disorder is noted on a soldier’s medical records and is 
taken into consideration for decisions regarding assignments.129  Particularly 
relevant to this case, U.S. Armed Forces routinely test for G6PD deficiency 
to ensure the safety of the uniformed personnel, making the deliberate 
choice to keep those who are G6PD deficient out of malarial zones or, in the 
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alternative, to provide them with an alternate anti-malarial drug.130  This is 
particularly noteworthy because of the prevalence of malaria in 
Afghanistan.131  If the G6PD test were deemed a genetic test, then deployed 
civilians would lack the same health protections afforded to uniform 
personnel. 
D.  An Argument for the Amendment of GINA 
Jeremy Gruber, an influential voice behind the scenes of the drafting of 
the language of GINA, testified that experts could think of no examples that 
warranted a business necessity exception.132  This, however, simply reflects 
a lack of consideration of the reality faced by those who work outside the 
traditional workplace.  Civilian employees of DOD, members of the State 
Department, and those employed by the Peace Corps, among others, often 
work in environments far removed from the stereotypical office setting and, 
as a result, face a range of different and difficult challenges.  The Peace 
Corps expressed legitimate concerns, informed in part by guidance provided 
by the CDC, when it initially refused to place Omulepu in a malarial region 
to prevent a potential negative reaction to the use of primaquine.133  Because 
GINA contains no business necessity exception, the Peace Corps was forced 
into entering a settlement—the type of dilemma similar employers will 
surely face in the future.134  Barring legislative change, more and more 
employers will find themselves in a position where, against their better 
judgment, they will knowingly place employees in harm’s way. 
A business necessity exception amendment to GINA, similar to the 
business necessity exception to the ADA, would help alleviate the potential 
threats faced by employees in non-traditional work environments.  While the 
business necessity exception to the ADA covers a “direct threat” to one’s 
self or others that arises out of a condition with physical manifestations, the 
exception to GINA would be for genetic conditions, like G6PD deficiency, 
which may manifest as a direct result of stressors or other conditions in the 
workplace.135  To prevent abuse of discretion, it is sound policy to require 
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that the employer have the burden of proving that no reasonable 
accommodation to ensure employee safety can be made prior to denying an 
employee or applicant a position based on a genetic condition.  Any business 
necessity exception that arises out of this proposed change should be 
extremely limited and carefully considered to prevent abuse as society 
continues to learn more about human genetics.  However, based on what we 
now know, such an exception has the ability to make work safer for those in 
both traditional and non-traditional workplace environments. 
CONCLUSION 
While uniformed members of the armed forces who test positive for 
G6PD deficiency are either not assigned to locations that would require them 
to take malaria medication or are given an anti-malarial medication other 
than primaquine,136 the G6PD status of Peace Corp, State Department, and 
DOD civilians, who are often in malaria-infested locations comparable to 
their uniformed colleagues, potentially cannot be factored into decisions 
about assignments under GINA.  This disparate treatment has the potential 
to pose a direct threat to the health of these civilian employees.  The Peace 
Corps specifically recognized the potential dangers of assigning G6PD 
deficient employees to malarial areas, stating in its response to Imoite 
Ipaalinyang Omulepu’s complaint that sending such a person to a location 
where primaquine is required would be not just irresponsible, but medically 
unethical.137  Though the Peace Corps maintains that their required blood 
test is not a request for genetic information,138 the Agency agreed in 
settlement to place Omulepu in a malaria-endemic region,139 going against 
what it believed to be medically ethical.  By pushing forward with this 
complaint, Omulepu is placing himself in potentially serious danger (a direct 
threat-to-self), in the form of an adverse reaction to primaquine as a result of 
his G6PD deficiency.140 
The facts therefore suggest that situations arise where a business necessity 
exception, or a direct threat to the health or safety of the employee or others 
rule similar to that found under the ADA, is warranted for the protection of 
individuals in the workplace.  If such testing were permitted in limited 
circumstances, such as under the conditions faced by the federal employees 
assigned to work in malaria-infested regions like Afghanistan and sub-
	  
 136. Baruch & Hudson, supra note 6, at 439; Witcop Email, supra note 129. 
 137. Complaint, supra note 133, at 9. 
 138. Id. 
 139. Stipulation and Order of Dismissal, Omulepu v. United States Peace Corps, No. 
1:12-cv-00988 (S.D.N.Y. Sept. 14, 2012). 
 140. See generally Murray, supra note 4, at 905. 
336 The Journal of Contemporary Health Law and Policy Vol. XXX:2 
	  
Saharan Africa, the threat of an adverse reaction to a common medication 
like primaquine could largely be avoided by military and civilians alike.  
Clearly these atypical workplaces were not contemplated when GINA was 
drafted. 
While critics may posit that such an exception is not required based on the 
reality of the workplace, the example faced by employees of the State 
Department, Peace Corps and civilians in the DOD sent to malarial regions 
suggests differently.  Looking more broadly, the case of G6PD deficiency is 
only one such example where a business necessity exception could benefit 
both employer and employee.  Recognizing that situations would need to be 
evaluated carefully to prevent discrimination, and similar to the ADA 
exception, the employer should have the burden of demonstrating an 
adequate justification for the need for genetic testing.141 Thus, amending 
GINA to have the flexibility of a business necessity exception is sound 
public policy for the safety of workers. 
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